NCT06962670Recruiting
Predicting Cancer Risk With Digital and Molecular Markers
Digital and Molecular Detection of Markers for Disease Risk Prediction, Improvement of Diagnostic Detection Accuracy and Implementation for Preventive Measures of Cancer - A Combined Case-control and Cohort Study
Source: ClinicalTrials.gov · Last updated 8 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this study is to identify new markers to predict the risk of developing cancer, primarily breast cancer. For this purpose, researchers will compare data obtained from cancer patients and healthy individuals. If characteristic differences are identified, e.g. in biomarkers, life style or family history, this may indicate a person's increased risk of developing cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1250 (estimated)
- First submitted
- 23 Aug 2023
- Start date
- 14 Sept 2024
- Primary completion date
- Sept 2025
- Lead sponsor
- University of Erlangen-Nürnberg Medical School
- Diseases
- Lung cancer, Colorectal cancer
- NCT number
- NCT06962670
What you commit to
- Study type: Interventional
- Planned participants: 1250
- From 14 Sept 2024 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known infection with HIV (Human Immunodeficiency Virus), HepA (Hepatitis A), HepB (Hepatitis B), HepC (Hepatitis C) or active SARS-CoV2 (Severe acute respiratory syndrome coronavirus type 2) infection
- Acute severe or potentially life-threatening illness, except those specified in inclusion criterion #4
Who the study is looking for
- Biological adult (at least 18 years old) women
- Written informed consent for study participation and processing of personal data
- Own smartphone that can run the BayPass mobile application and willingness to use said smartphone for study purposes
- Additional inclusion criterion for case group:
- Pre-existing or current diagnosis of at least one of the following oncological diseases: breast cancer, lung cancer, colorectal cancer, gynecologic cancer (incl. ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, vaginal cancer and vulvar cancer)
Age in the registry: 18 years to - · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| DigiOnko Präventionsmobil Coordinator of this site? Confirm its status | Please Refer to Project Homepage For Details (see Link Below) | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.